SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Exelixis, Inc. (EXEL)
An SI Board Since January 2001
Posts SubjectMarks Bans Symbol
930 66 0 EXEL
Emcee:  kinkblot Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
205gs: EXEL(IL/N): Expect increasingly visible pipeline in 2006 12/6/05 52-Week Rmopgcw-12/19/2005
204great presentation. trying to turn the GSK corner, with an eye on leverage. phscaram(o)uche-12/6/2005
203slide 3 had two more xceptor targets, let's see where the discussion goes. scaram(o)uche-12/6/2005
202When I moved recently, got a place with a protected, south-facing deck over the scaram(o)uche-12/6/2005
201And the answer to wilder's questions is "yes" Message 20575915rkrw-12/6/2005
200Exelixis and Bristol-Myers Squibb Sign New Collaboration Agreement to Develop Nonigel bates-12/6/2005
199Artemis Pharmaceuticals and the Medical Research Council Sign License Agreement scaram(o)uche-12/5/2005
198CIBASA and Artemis Pharmaceuticals Sign Agreement for Marketing Wednesday Novembscaram(o)uche-11/21/2005
197[x999 at eortc/aacr. PR.] Data From Phase I Trial of Exelixis' XL999 Estabkeokalani'nui-11/17/2005
196PHILADELPHIA, Nov. 15 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) toLJM-11/15/2005
195Conference PHILADELPHIA, Nov. 15 /PRNewswire-FirstCall/ -- Exelixis, Inc. (LJM-11/15/2005
194Uh Oh. Side effects. (Thanks to rick for linking to the abstracts.) aacr/eortc keokalani'nui-11/14/2005
193x418 inhibits AKT and S6K and who knows what else. IND06. Message 21866742 Nkeokalani'nui-11/10/2005
192gbmf and pten. Thanks ice: Message 21872322 Thanks rick: Message 21871765 (keokalani'nui-11/10/2005
191Groupie, Finally got the cc. I had no idea exel had a gleevec t351 resistance carkrw-11/7/2005
190A261 A Phase 1 Dose-escalation and Pharmacokinetic (PK) Study of a Novel Spectruscaram(o)uche-11/3/2005
189shhh. scangos is trying to tell us something in the Q-call, but he can't rekeokalani'nui-11/3/2005
188Exelixis Announces Third Quarter 2005 Financial Results Thursday November 3, 4:0mopgcw-11/3/2005
187Exelixis to Host Clinical Investigator Discussions of Preliminary Phase I Trial keokalani'nui-11/2/2005
186Data From Exelixis Phase I Clinical Trials of Xl647, Xl999 and Xl880 to Be Presekeokalani'nui-10/11/2005
185Exelixis Starts Three New Phase I Clinical Trials for Novel Compounds XL844, XL1mopgcw-9/22/2005
184One word for Scangos needs to hear: Kadus. Cheers, Tucktuck-9/6/2005
183<i>[Genomica] approached Exelixis, which acquired the company, kept the caDewDiligence_on_SI-9/5/2005
182bizjournals.com San Francisco Business Times From the September 5, 2005 print rkrw-9/5/2005
181GS: EXEL(IL/N): Update from meeting w/ mgmt. Pipeline progressing well. 52-Weemopgcw-8/22/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News